Clinical Trial

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2022-07-12; most recent amendment 2026-06-23.
Status change: Recruiting → Active, Not Recruiting 2025-08-20
Status change: Not Yet Recruiting → Recruiting 2022-09-08
Trial Details
NCT Number NCT05461170
Lead Sponsor Vir Biotechnology, Inc.
Conditions Hepatitis D, Chronic
Enrollment 95 participants
Start Date 2022-09-17
Primary Completion 2031-11 (estimated)
Study Completion 2032-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-26